10-Q quarterly report · filed Nov 9, 2026

ImmunityBio, Inc. (IBRX) Q3 2026 10-Q Quarterly Report

Short answer

ImmunityBio, Inc. (IBRX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $49M (up 52.3% year over year) with net income of −$185M.

Q3 2026 key financials · XBRL

Revenue
$49M
+52.3% YoY · −4.7% QoQ
Net income
−$185M
−174.4% YoY · +19.9% QoQ
Operating margin
-159.7%
EPS (diluted)
−$0.17
−183.3% YoY · +19.0% QoQ

Source: XBRL data from the ImmunityBio, Inc. (IBRX) Q3 2026 10-Q on SEC EDGAR. USD.

ImmunityBio, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $48.8M, up from $32.1M YoY, driven by ANKTIVA product revenue of $48.7M, up 53%
  • Operating loss $78.0M vs $55.6M YoY, operating margin (159.7%) vs (173.5%)
  • ANKTIVA best-performing product, revenue increased $17.0M; no segment disclosures
  • Cash, equivalents and marketable securities $334.3M vs $242.8M at December 31, 2025
  • Outlook: R&D expenses expected to increase significantly; substantial additional funding required, with going-concern doubt absent support

Risk Factors

  • Newly expanded ANKTIVA indication: FDA approval on October 14, 2026 for BCG-unresponsive NMIBC with high-grade papillary-only tumors
  • Regulatory compliance: QUILT-3.032 completion and annual FDA reporting required through 2029
  • Near-term market risk: ongoing TICE BCG shortage constraining ANKTIVA uptake and clinical-trial execution
  • Liquidity risk: $334.3 million cash and securities versus $480.0 million convertible note and over $426.3 million RIPA liability
  • RIPA exposure: revenue-interest payments ranging from 5.625% to 12.50% of worldwide net sales excluding China

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ImmunityBio, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.